


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

 Form PTO-1449 (Modified)
 Use several sheets if necessary

Sheet 1 of 1

COMPLETE IF KNOWN

| | |
|----------------------|-----------------------|
| Application Number | 10/567,470 |
| Confirmation Number | 4986 |
| Filing Date | November 30, 2006 |
| First Named Inventor | Iversen <i>et al.</i> |
| Group Art Unit | 1635 |
| Examiner Name | Angell, Jon E. |
| Attorney Docket No. | 50450-8055.US00 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. | U.S. Patent or Application | | Name of Patentee or Inventor of Cited Document | Date of Publication or Filing Date of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|----------|----------------------------|----------------------|--|--|---|
| | | NUMBER | Kind Code (if known) | | | |
| | 1. | US-5,194,428 | | Agrawal <i>et al.</i> | 03-16-1993 | |
| | 2. | US-5,801,154 | | Baracchini <i>et al.</i> | 09-01-1998 | |
| | 3. | US-5,892,023 | | Pirotzky <i>et al.</i> | 04-06-1999 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent or Application | | Name of Patentee or Applicant of Cited Document | Date of Publication or Filing Date of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|----------|-------------------------------|--------------|---|--|---|---|
| | | Office | NUMBER | Kind Code (if known) | | | |
| | 4. | PCT | WO 06/047683 | A2 | AVI Biopharma, Inc. | 04-05-2006 | |

OTHER NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|---|---|
| | 5. | Agrawal <i>et al.</i> "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus", <i>Proc Natl Acad Sci U S A.</i> , 85(19):7079-7083 (1988). | |
| | 6. | Basler <i>et al.</i> , "The Ebola virus VP35 protein functions as a type I IFN antagonist", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 97(22):12289-12294 (2000). | |
| | 7. | Copy of the International Search Report and Written Opinion for PCT/US2007/011435, search report dated, September 29, 2008, 10 pages (2008). | |
| | 8. | Crooke, S. T., <i>Antisense Drug Technology: Principles, Strategies, and Applications</i> . New York, Marcel Dekker, S. Crooke Ed Springer Pages 1-50 (1999). | |
| | 9. | Jen <i>et al.</i> , "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies", <i>Stem Cells</i> , 18:307-319 (2000). | |
| | 10. | Scanlon, K.I., "Anti-genes: siRNA, ribozymes and antisense", <i>Current Pharmaceutical Biotechnology</i> , 5(5):415-420 (2004). | |
| | 11. | Taylor <i>et al.</i> , "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination", <i>Drug Discovery Today</i> , 4:562-567 (1999). | |

| | |
|--|-------------------------------|
| EXAMINER /Jon Eric Angell/ | DATE CONSIDERED 05/06/2010 |
| *EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s). | |